RXRX vs. KYMR, SDGR, PTCT, RCUS, VIE, PCVX, RVMD, EXEL, HALO, and CRSP
Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Kymera Therapeutics (KYMR), Schrödinger (SDGR), PTC Therapeutics (PTCT), Arcus Biosciences (RCUS), Viela Bio (VIE), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), and CRISPR Therapeutics (CRSP). These companies are all part of the "medical" sector.
Recursion Pharmaceuticals (NASDAQ:RXRX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Kymera Therapeutics has higher revenue and earnings than Recursion Pharmaceuticals. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 15.8% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 15.8% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Kymera Therapeutics has a net margin of -194.67% compared to Recursion Pharmaceuticals' net margin of -765.90%. Kymera Therapeutics' return on equity of -31.92% beat Recursion Pharmaceuticals' return on equity.
Kymera Therapeutics received 19 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. However, 51.22% of users gave Recursion Pharmaceuticals an outperform vote while only 48.19% of users gave Kymera Therapeutics an outperform vote.
In the previous week, Kymera Therapeutics had 2 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 10 mentions for Kymera Therapeutics and 8 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.75 beat Kymera Therapeutics' score of 0.41 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.
Recursion Pharmaceuticals presently has a consensus price target of $14.33, indicating a potential upside of 67.06%. Kymera Therapeutics has a consensus price target of $42.70, indicating a potential upside of 31.43%. Given Recursion Pharmaceuticals' higher probable upside, equities analysts plainly believe Recursion Pharmaceuticals is more favorable than Kymera Therapeutics.
Recursion Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500.
Summary
Kymera Therapeutics beats Recursion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Recursion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Recursion Pharmaceuticals Competitors List
Related Companies and Tools
